Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | WHR1 | P49842 | 5/20 | 0.39 |
| ▸ | KIF18A | Q8NI77 | 7/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22119456 | 0.84 | P2RX3 (0.42) | WHR1 | |
| SCHEMBL26646283 | 0.76 | RBP4 (0.58) | KCNQ3KCNQ2WHR1KIF18ARBP4 | |
| SCHEMBL30600681 | 0.76 | RBP4 (0.58) | KCNQ3KCNQ2WHR1KIF18ARBP4 | |
| SCHEMBL22119481 | 0.75 | HIF1A (0.41) | MAOBPIK3CAPIK3CB | |
| SCHEMBL22119556 | 0.75 | RBP4 (0.44) | KCNQ3KCNQ2WHR1KIF18ARBP4 | |
| SCHEMBL22155678 | 0.73 | KIF18A (0.68) | KIF18A | |
| SCHEMBL26744703 | 0.72 | RBP4 (0.44) | KCNQ3KCNQ2WHR1KIF18ARBP4 | |
| SCHEMBL28608216 | 0.71 | TDP1 (0.45) | KCNQ3KCNQ2HRH1HRH4RET | |
| SCHEMBL30615839 | 0.69 | RBP4 (0.54) | KCNQ3KCNQ2RETKIF18ARBP4 | |
| SCHEMBL20746083 | 0.69 | CRBN (0.59) | KCNQ3KCNQ2KIF18ARBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236069-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200239441-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2020-07-30 | — | — | US | disclosed |
| WO-2020132648-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239441-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | KCNQ3 2199/4885KCNQ2 1733/4885HRH1 4265/4885 |
| US-11236069-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | KCNQ3 2199/4885KCNQ2 1733/4885HRH1 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.